TrialCardiovascular diabetology2017

A randomised study of the impact of the SGLT2 inhibitor dapagliflozin on microvascular and macrovascular circulation.

Christian Ott et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.